Smith JA, Kitt MM, Morice AH, et al. MK-7264, a P2X3 Receptor Antagonist, Reduces Cough Frequency in Patients with Refractory Chronic Cough: Results from a Randomized, Controlled, Phase 2b Clinical Trial. ATS 2017, A7608.
Fase IIb-onderzoek naar het M72/AS01E-vaccin ter preventie van tbc
jan 2019 | Vaccinatie